|
1
|
Sanyal AJ: Past, present and future
perspectives in nonalcoholic fatty liver disease. Nat Rev
Gastroenterol Hepatol. 16:377–386. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Friedman SL, Neuschwander-Tetri BA,
Rinella M and Sanyal AJ: Mechanisms of NAFLD development and
therapeutic strategies. Nat Med. 24:908–922. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
European Association for the Study of the
Liver (EASL); European Association for the Study of Diabetes
(EASD); European Association for the Study of Obesity (EASO).
EASL-EASD-EASO clinical practice guidelines for the management of
non-alcoholic fatty liver disease. J Hepatol. 64:1388–1402.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ekstedt M, Franzén LE, Mathiesen UL,
Thorelius L, Holmqvist M, Bodemar G and Kechagias S: Long-term
follow-up of patients with NAFLD and elevated liver enzymes.
Hepatology. 44:865–873. 2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ekstedt M, Nasr P and Kechagias S: Natural
history of NAFLD/NASH. Curr Hepatol Rep. 16:391–397.
2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Suzuki A and Diehl AM: Nonalcoholic
steatohepatitis. Annu Rev Med. 68:85–98. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yang J, Fernández-Galilea M,
Martínez-Fernández L, González-Muniesa P, Pérez-Chávez A, Martínez
JA and Moreno-Aliaga MJ: Oxidative stress and non-alcoholic fatty
liver disease: Effects of omega-3 fatty acid supplementation.
Nutrients. 11(872)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mendez-Sanchez N, Cruz-Ramon VC,
Ramirez-Perez OL, Hwang JP, Barranco-Fragoso B and Cordova-Gallardo
J: New aspects of lipotoxicity in nonalcoholic steatohepatitis. Int
J Mol Sci. 19(2034)2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kim KH and Lee MS: Pathogenesis of
nonalcoholic steatohepatitis and hormone-based therapeutic
approaches. Front Endocrinol (Lausanne). 9(485)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Masarone M, Rosato V, Dallio M, Gravina
AG, Aglitti A, Loguercio C, Federico A and Persico M: Role of
oxidative stress in pathophysiology of nonalcoholic fatty liver
disease. Oxid Med Cell Longev. 2018(9547613)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bocsan IC, Milaciu MV, Pop RM, Vesa SC,
Ciumarnean L, Matei DM and Buzoianu AD: Cytokines
genotype-phenotype correlation in nonalcoholic steatohepatitis.
Oxid Med Cell Longev. 2017(4297206)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tarantino G, Citro V and Capone D:
Nonalcoholic fatty liver disease: A challenge from mechanisms to
therapy. J Clin Med. 9(15)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Stojsavljević S, Gomerčić Palčić M,
Virović Jukić L, Smirčić Duvnjak L and Duvnjak M: Adipokines and
proinflammatory cytokines, the key mediators in the pathogenesis of
nonalcoholic fatty liver disease. World J Gastroenterol.
20:18070–18091. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lindenmeyer CC and McCullough AJ: The
natural history of nonalcoholic fatty liver disease-an evolving
view. Clin Liver Dis. 22:11–21. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Stål P: Liver fibrosis in non-alcoholic
fatty liver disease-diagnostic challenge with prognostic
significance. World J Gastroenterol. 21:11077–11087.
2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Petta S, Maida M, Macaluso FS, Di Marco V,
Camma C, Cabibi D and Craxı A: The severity of steatosis influences
liver stiffness measurement in patients with nonalcoholic fatty
liver disease. Hepatology. 62:1101–1110. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Furlong CE, Marsillach J, Jarvik GP and
Costa LG: Paraoxonases-1, -2 and -3: What are their functions? Chem
Biol Interact. 259:51–62. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Shokri Y, Variji A, Nosrati M,
Khonakdar-Tarsi A, Kianmehr A, Kashi Z, Bahar A, Bagheri A and
Mahrooz A: Importance of paraoxonase 1 (PON1) as an antioxidant and
antiatherogenic enzyme in the cardiovascular complications of type
2 diabetes: Genotypic and phenotypic evaluation. Diabetes Res Clin
Pract. 161(108067)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ciumarnean L, Milaciu MV, Macarie AE,
Sampelean DP and Achimas-Cadariu A: Non-genetic factors influencing
serum PON1 levels. HVM Bioflux. 6:20–24. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Marsillach J, Aragonès G, Mackness B,
Mackness M, Rull A, Beltrán-Debón R, Pedro-Botet J,
Alonso-Villaverde C, Joven J and Camps J: Decreased paraoxonase-1
activity is associated with alterations of high-density lipoprotein
particles in chronic liver impairment. Lipids Health Dis.
9(46)2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Marsillach J, Camps J, Ferre N, Beltran R,
Rull A, Mackness B, Mackness M and Joven J: Paraoxonase-1 is
related to inflammation, fibrosis and PPAR delta in experimental
liver disease. BMC Gastroenterol. 9(3)2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Fuhrman B: Regulation of Hepatic
Paraoxonase-1 expression. J Lipids. 2012(684010)2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Samy W and Hassanian MA: Paraoxonase-1
activity, malondialdehyde and glutathione peroxidase in
non-alcoholic fatty liver disease and the effect of atorvastatin.
Arab J Gastroenterol. 12:80–85. 2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lou-Bonafonte JM, Gabás-Rivera C, Navarro
MA and Osada J: PON1 and mediterranean diet. Nutrients.
7:4068–4092. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Jia Y, Zhong F, Jiang S, Guo Q, Jin H,
Wang F, Li M, Wang L, Chen A, Zhang F, et al: Periostin in chronic
liver diseases: Current research and future perspectives. Life Sci.
226:91–97. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kumar P, Smith T, Raeman R, Chopyk DM,
Brink H, Liu Y, Sulchek T and Anania FA: Periostin promotes liver
fibrogenesis by activating lysyl oxidase in hepatic stellate cells.
J Biol Chem. 293:12781–12792. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ratziu V, Bellentani S, Cortez-Pinto H,
Day C and Marchesini G: A position statement on NAFLD/NASH based on
the EASL 2009 special conference. J Hepatol. 53:372–384.
2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Angulo P, Hui JM, Marchesini G, Bugianesi
E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, et
al: The NAFLD fibrosis score: A noninvasive system that identifies
liver fibrosis in patients with NAFLD. Hepatology. 45:846–854.
2007.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Drescher HK, Weiskirchen S and Weiskirchen
R: Current status in testing for nonalcoholic fatty liver disease
(NAFLD) and nonalcoholic steatohepatitis (NASH). Cells.
8(845)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ratziu V: A critical review of endpoints
for non-cirrhotic NASH therapeutic trials. J Hepatol. 68:353–361.
2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Dyson JK, Anstee QM and McPherson S:
Non-alcoholic fatty liver disease: A practical approach to
diagnosis and staging. Frontline Gastroenterol. 5:211–218.
2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Younossi ZM, Loomba R, Anstee QM, Rinella
ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L,
Negro F, Caldwell SH, et al: Diagnostic modalities for nonalcoholic
fatty liver disease, nonalcoholic steatohepatitis, and associated
fibrosis. Hepatology. 68:349–360. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Xiao G, Zhu S, Xiao X, Yan L, Yang J and
Wu G: Comparison of laboratory tests, ultrasound, or magnetic
resonance elastography to detect fibrosis in patients with
nonalcoholic fatty liver disease: A meta-analysis. Hepatology.
66:1486–1501. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Castera L, Friedrich-Rust M and Loomba R:
Noninvasive assessment of liver disease in patients with
nonalcoholic fatty liver disease. Gastroenterology.
156:1264–1281.e4. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yang M, Jiang L, Wang Y, Li X, Zou Z, Han
T, Nan Y, Lu F and Zhao J: Step layered combination of noninvasive
fibrosis models improves diagnostic accuracy of advanced fibrosis
in nonalcoholic fatty liver disease. J Gastrointestin Liver Dis.
28:289–296. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Levy D, Reichert CO and Bydlowski SP:
Paraoxonases activities and polymorphisms in elderly and old-age
diseases: An overview. Antioxidants (Basel). 8(118)2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Milaciu MV, Vesa ȘC, Bocșan IC, Ciumărnean
L, Sâmpelean D, Negrean V, Pop RM, Matei DM, Pașca S, Răchișan AL,
et al: Paraoxonase-1 serum concentration and PON1 gene
polymorphisms: Relationship with non-alcoholic fatty liver disease.
J Clin Med. 8(2200)2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ciumarnean L, Vesa SC, Dronca E, Sampelean
DP, Vlad VC, Moldovan MS and Achimaş CA: Distribution of
paraoxonase 1 polymorphisms and activities in obese patients. Rev
Romana Med Lab. 21:381–389. 2013.
|
|
39
|
Ciumarnean L, Dronca E, Vesa SC, Sampelean
D, Buzoianu AD and Achimas-Cadariu A: Paraoxonase 1
genotype-phenotype correlation in patients with metabolic syndrome.
Rom J Morphol Embryol. 56:387–392. 2015.PubMed/NCBI
|
|
40
|
Tisato V, Romani A, Tavanti E, Melloni E,
Milani D, Bonaccorsi G, Sanz JM, Gemmati D, Passaro A and
Cervellati C: Crosstalk between adipokines and paraoxonase 1: A new
potential axis linking oxidative stress and inflammation.
Antioxidants (Basel). 8(287)2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Marín M, Moya C and Máñez S: Mutual
influences between nitric oxide and paraoxonase 1. Antioxidants
(Basel). 8(619)2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Amara S, Lopez K, Banan B, Brown SK,
Whalen M, Myles E, Ivy MT, Johnson T, Schey KL and Tiriveedhi V:
Synergistic effect of pro-inflammatory TNFα and IL-17 in periostin
mediated collagen deposition: Potential role in liver fibrosis. Mol
Immunol. 64:26–35. 2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lv Y, Wang W, Jia WD, Sun QK, Huang M,
Zhou HC, Xia HH, Liu WB, Chen H, Sun SN and Xu GL: High
preoparative levels of serum periostin are associated with poor
prognosis in patients with hepatocellular carcinoma after
hepatectomy. Eur J Surg Oncol. 39:1129–1135. 2013.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Takeda K, Noguchi R, Kitade M, Namisaki T,
Moriya K, Kawaratani H, Okura Y, Kaji K, Aihara Y, Douhara A, et
al: Periostin cross-reacts with the renin-angiotensin system during
liver fibrosis development. Mol Med Rep. 16:5752–5758.
2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Seo YY, Cho YK, Bae JC, Seo MH, Park SE,
Rhee EJ, Park CY, Oh KW, Park SW and Lee WY: Tumor necrosis
factor-α as a predictor for the development of nonalcoholic fatty
liver disease: A 4-year follow-up study. Endocrinol Metab (Seoul).
28:41–45. 2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Jamali R, Arj A, Razavizade M and Aarabi
MH: Prediction of nonalcoholic fatty liver disease via a novel
panel of serum adipokines. Medicine (Baltimore).
95(e2630)2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Manco M, Marcellini M, Giannone G and
Nobili V: Correlation of serum TNF-alpha levels and histologic
liver injury scores in pediatric nonalcoholic fatty liver disease.
Am J Clin Pathol. 127:954–960. 2007.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Niederreiter L and Tilg H: Cytokines and
fatty liver disease. Liv Res. 2:14–20. 2018.
|
|
49
|
Copaci I, Micu L and Voiculescu M: The
role of cytokines in non-alcoholic steatohepatitis. A review. J
Gastrointestin Liv Dis. 15:363–373. 2006.PubMed/NCBI
|
|
50
|
Yang YM and Seki E: TNFα in liver
fibrosis. Curr Pathobiol Rep. 3:253–261. 2015.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Lopetuso LR, Mocci G, Marzo M, D'Aversa F,
Rapaccini GL, Guidi L, Armuzzi A, Gasbarrini A and Papa A: Harmful
effects and potential benefits of anti-tumor necrosis factor
(TNF)-α on the liver. Int J Mol Sci. 19(2199)2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Petta S, Eslam M, Valenti L, Bugianesi E,
Barbara M, Camma C, Porzio M, Rosso C, Fargion S, George J and
Craxì A: Metabolic syndrome and severity of fibrosis in
nonalcoholic fatty liver disease: An age-dependent risk profiling
study. Liver Int. 37:1389–1396. 2017.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Culafic M, Vezmar Kovacevic S, Dopsaj V,
Stulic M, Vlaisavljevic Z, Miljkovic B and Culafic D: A simple
index for nonalcoholic steatohepatitis-HUFA-Based on routinely
performed blood tests. Medicina (Kaunas). 55(243)2019.PubMed/NCBI View Article : Google Scholar
|
